Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
61 participants
INTERVENTIONAL
2011-08-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
NCT02240693
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
NCT02337907
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
NCT00722046
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
NCT00329082
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo/VI-1121
Subjects received placebo during first treatment period and active treatment with VI-1121 during the second treatment period.
VI-1121
Placebo
VI-1121/Placebo
Subjects received active treatment with VI-1121 during the first treatment period and placebo during the second treatment period.
VI-1121
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VI-1121
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CT or MRI within 2 years prior to study
* stable dose of current Alzheimer's treatment for at least 3 months
Exclusion Criteria
* history of cerebrovascular disease or myocardial infarction within 6 months
60 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medpace, Inc.
INDUSTRY
VIVUS LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Francisco, California, United States
Santa Monica, California, United States
Sunrise, Florida, United States
Louisville, Kentucky, United States
Las Vegas, Nevada, United States
Toms River, New Jersey, United States
New Windsor, New York, United States
Durham, North Carolina, United States
Raleigh, North Carolina, United States
Toledo, Ohio, United States
Plano, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.